Research programme: peptide therapeutics - Altus Pharmaceuticals

Drug Profile

Research programme: peptide therapeutics - Altus Pharmaceuticals

Alternative Names: ALTU-141; ALTU-242; ALTU-244

Latest Information Update: 16 Sep 2016

Price : $50

At a glance

  • Originator Altus Pharmaceuticals
  • Class Enzymes
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gout; Inflammatory bowel diseases; Neonatal jaundice

Most Recent Events

  • 16 Sep 2016 Discontinued - Preclinical for Gout in USA (PO) (Altus pipeline; September 2016)
  • 15 Jun 2009 Suspended - Preclinical for Gout in USA (PO)
  • 15 Mar 2007 ALTU 242 is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top